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year (Ca/Tx). The Ca/Tx group was more likely to re-
ceive family care (34% vs. 26% for the Ca/No Tx and
the No Ca groups, P.05), and received significantly
more weekly hours of care (10.2 hours vs. 6.6 for the Ca/
No Tx and 7.0 for the No Ca groups, P.05) The aver-
age absolute increase in weekly family caregiving hours
for the Ca/Tx group (3.2 hours) represents an annual
cost of over $1.1 billion in the US. CONCLUSION: Fam-
ily caregiving costs for the elderly with cancer are sub-
stantial and should be considered when estimating the
cost of cancer treatment in the elderly.
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OBJECTIVE: To perform a cost-utility analysis compar-
ing paclitaxel, docetaxel, mitomycine plus vinorelbine
and standard therapy considering clinical efficacy, qual-
ity-adjusted-life-years and costs. METHODS: A decision
model was constructed for this cost-utility analysis. Clin-
ical efficacy data were collected by literature review and
expert opinion. Two-phase III clinical trials using pacli-
taxel, docetaxel, and one recent phase II trial using com-
bination therapy of vinorelbine plus mitomycin were
cited for evaluating the transition probabilities of health
status along the model arms. Standard therapy consisted
of mitomycin plus vinblastine. Utility data and cost data
were collected from literature, data from previous iMTA
studies and the Dutch Pharmaceutical Compass. The
study was conducted from the hospital perspective and
only direct medical costs were taken into account. The
base year was 1998. RESULTS: Vinorelbine plus mito-
mycin has the lowest incremental cost-effectiveness ratio
of US$17114 per quality adjusted life year (QALY) (1
US$  2.3 NLG), followed by paclitaxel of US$ 30,270
per QALY, and docetaxel of US$49,739 per QALY. Fur-
thermore, vinorelbine plus mitomycin has the highest
QALY value of 0.43, compared to paclitaxel (0.35), doc-
etaxel (0.34) and mitomycin/vinblastin (0.29). Compared
to the standard therapy incremental cost-effectiveness of
vinorelbine/mitomycin is US$23,046 per QALY, which is
the lowest of all alternatives. CONCLUSION: Vinorel-
bine plus mitomycin is the most cost-effective second-line
chemotherapy for metastatic breast cancer patients com-
pared to paclitaxel, docetaxel and standard chemother-
apy with mitomycin/vinblastin.
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OBJECTIVES: To develop a clinical/economic decision
analysis model to estimate the costs, cost-effectiveness,
and usage probabilities of current treatments for early,
recurrent, and metastatic breast cancer in six countries
(U.S., U.K., Germany, Italy, France, Japan). METHODS:
Breast cancer treatment guidelines developed by a U.S.
oncology provider network (NCCN) were used as the ini-
tial basis for developing decision analysis-based treat-
ment pathways by disease stage. These guidelines were
modified to reflect current treatment patterns in each
country via a series of panel discussions with breast can-
cer thoughtleaders representing the six countries. The
multi-national treatment pathways were then validated
by six additional thought leader panels (one panel per
country, two to four participants per panel). For each
country, the probability distribution for every decision
node in the pathway was obtained from market research
or thought leader expert opinion. For each therapy, costs
were obtained from standardized databases, government
sources, published literature, and a provider survey for
the following categories: drug acquisition and adminis-
tration, monitoring, adverse event treatments, and hospi-
talization. RESULTS: Inputting the country-specific proba-
bility data into the multi-national pathway structure
generated 24 unique decision models (4 breast cancer
stages per country). In total, the model includes over 70
unique treatments for breast cancer and has approxi-
mately 144 million decision nodes when all treatment
combinations are considered. The model generates the
following outcomes for each country: rates of treatment
and treatment scenarios, cost per treatment, probable
cost per patient, and cost-effectiveness. The model also
examines the effect of varying cost and probability sce-
narios to reflect country-specific treatment practices and
international variations. CONCLUSIONS: When devel-
oping a comprehensive, multi-national model of an entire
disease, using clinical guidelines and thought leader input
as a basis can generate a valuable decision-making tool
used to examine the economic impact of existing and de-
velopment products as well as identifying cost-effective
treatment pathways.
